Publications

Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

 96
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

Tags:

Previous Article

Human Schwann cell lipid dysregulation and plasma membrane perturbation in Charc...

Next Article

FerroTerminator1 as a potent therapeutic drug for MASH

Related Posts

Bi-allelic variants in WDR47 cause a complex neurodevelopmental syndrome

Bi-allelic variants in WDR47 cause a complex neurodevel...

 119

Muscle-derived Mimecan regulates hypothalamus- brown adipose tissue communication and promotes health and lifespan in mice

Muscle-derived Mimecan regulates hypothalamus- brown ad...

 46

Decoding the language of PLK1 docking motifs and activation mechanisms

Decoding the language of PLK1 docking motifs and activa...

 158